XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 45.31

Change

+0.70 (+1.57)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.56 (+0.36%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

+0.29 (+0.39%)

USD 3.02B
FXH First Trust Health Care AlphaD..

+0.84 (+0.75%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+1.18 (+1.31%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.23 (+0.94%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.98 (+2.59%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.11 (-0.11%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.35 (+1.18%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.87 (+1.35%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.77 (+2.70%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.87% 14% F 52% F
Dividend Return 0.79% 87% B+ 19% F
Total Return 9.66% 29% F 47% F
Trailing 12 Months  
Capital Gain 11.38% 5% F 43% F
Dividend Return 1.24% 72% C 17% F
Total Return 12.62% 5% F 37% F
Trailing 5 Years  
Capital Gain 20.51% 24% F 57% F
Dividend Return 4.35% 67% D+ 12% F
Total Return 24.85% 33% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 0.26% 19% F 39% F
Dividend Return 0.94% 19% F 31% F
Total Return 0.69% 68% D+ 15% F
Risk Return Profile  
Volatility (Standard Deviation) 15.39% 62% D 63% D
Risk Adjusted Return 6.12% 19% F 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.